Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Feith

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Biorxiv : the Preprint Server for Biology|April 25, 2024
Acute myeloid leukemia mitochondria hydrolyze ATP to resist chemotherapyJames T Hagen, Mclane M Montgomery, Raphael T Aruleba, et al.
Blood Advances|January 3, 2024
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypesB Bishal Paudel, Su-Fern Tan, Todd E Fox, et al.
Oncotarget|November 9, 2016
Acid ceramidase is upregulated in AML and represents a novel therapeutic targetSu-Fern Tan, Xin Liu, Todd E Fox, et al.
Blood Advances|December 10, 2025
Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-FunctionDanielle E Arnold, Saara Kaviany, Jahnavi Aluri, et al.
Science Advances|April 9, 2025
Acute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapyJames T Hagen, McLane M Montgomery, Raphael T Aruleba, et al.
Blood Neoplasia|April 17, 2026
Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemiaJohnson Ung, Su-Fern Tan, Jeremy J P Shaw, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia via a cytotoxic integrated stress responseJohnson Ung, Su-Fern Tan, Jeremy J P Shaw, et al.
Nature Genetics|May 5, 2022
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalkConstance Baer, Shunsuke Kimura, Mitra S Rana, et al.
Blood Advances|September 7, 2019
Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemiaBrian M Barth, Weiyuan Wang, Paul T Toran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma SubtypesBimarzhan Assatova, Robert Willim, Christopher Trevisani, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Biorxiv : the Preprint Server for Biology|April 25, 2024
Acute myeloid leukemia mitochondria hydrolyze ATP to resist chemotherapyJames T Hagen, Mclane M Montgomery, Raphael T Aruleba, et al.
Blood Advances|January 3, 2024
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypesB Bishal Paudel, Su-Fern Tan, Todd E Fox, et al.
Oncotarget|November 9, 2016
Acid ceramidase is upregulated in AML and represents a novel therapeutic targetSu-Fern Tan, Xin Liu, Todd E Fox, et al.
Blood Advances|December 10, 2025
Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-FunctionDanielle E Arnold, Saara Kaviany, Jahnavi Aluri, et al.
Science Advances|April 9, 2025
Acute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapyJames T Hagen, McLane M Montgomery, Raphael T Aruleba, et al.
Blood Neoplasia|April 17, 2026
Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemiaJohnson Ung, Su-Fern Tan, Jeremy J P Shaw, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia via a cytotoxic integrated stress responseJohnson Ung, Su-Fern Tan, Jeremy J P Shaw, et al.
Nature Genetics|May 5, 2022
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalkConstance Baer, Shunsuke Kimura, Mitra S Rana, et al.
Blood Advances|September 7, 2019
Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemiaBrian M Barth, Weiyuan Wang, Paul T Toran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma SubtypesBimarzhan Assatova, Robert Willim, Christopher Trevisani, et al.
Pageof 8